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CERTL reduces C16 ceramide, amyloid-β
levels, and inflammation in a model of
Alzheimer’s disease
Simone M. Crivelli1,2,3†, Qian Luo1†, Jo A.A. Stevens1, Caterina Giovagnoni1, Daan van Kruining1, Gerard Bode1,
Sandra den Hoedt4, Barbara Hobo5, Anna-Lena Scheithauer6, Jochen Walter6, Monique T. Mulder4,
Christopher Exley7, Matthew Mold7, Michelle M. Mielke8, Helga E. De Vries9, Kristiaan Wouters10,11,
Daniel L. A. van den Hove12, Dusan Berkes13, María Dolores Ledesma14, Joost Verhaagen5, Mario Losen1,
Erhard Bieberich2,3 and Pilar Martinez-Martinez1*

Abstract
Background: Dysregulation of ceramide and sphingomyelin levels have been suggested to contribute to the
pathogenesis of Alzheimer’s disease (AD). Ceramide transfer proteins (CERTs) are ceramide carriers which are crucial
for ceramide and sphingomyelin balance in cells. Extracellular forms of CERTs co-localize with amyloid-β (Aβ)
plaques in AD brains. To date, the significance of these observations for the pathophysiology of AD remains
uncertain.
Methods: A plasmid expressing CERTL, the long isoform of CERTs, was used to study the interaction of CERTL with
amyloid precursor protein (APP) by co-immunoprecipitation and immunofluorescence in HEK cells. The
recombinant CERTL protein was employed to study interaction of CERTL with amyloid-β (Aβ), Aβ aggregation
process in presence of CERTL, and the resulting changes in Aβ toxicity in neuroblastoma cells. CERTL was
overexpressed in neurons by adeno-associated virus (AAV) in a mouse model of familial AD (5xFAD). Ten weeks
after transduction, animals were challenged with behavior tests for memory, anxiety, and locomotion. At week 12,
brains were investigated for sphingolipid levels by mass spectrometry, plaques, and neuroinflammation by
immunohistochemistry, gene expression, and/or immunoassay.
Results: Here, we report that CERTL binds to APP, modifies Aβ aggregation, and reduces Aβ neurotoxicity in vitro.
Furthermore, we show that intracortical injection of AAV, mediating the expression of CERTL, decreases levels of
ceramide d18:1/16:0 and increases sphingomyelin levels in the brain of male 5xFAD mice. CERTL in vivo overexpression has a mild effect on animal locomotion, decreases Aβ formation, and modulates microglia by decreasing
their pro-inflammatory phenotype.
(Continued on next page)
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Conclusion: Our results demonstrate a crucial role of CERTL in regulating ceramide levels in the brain, in amyloid
plaque formation and neuroinflammation, thereby opening research avenues for therapeutic targets of AD and
other neurodegenerative diseases.
Keywords: Ceramide, Sphingomyelin, Ceramide transporter protein (CERT), Adeno-associated virus (AAV),
Alzheimer’s disease (AD), 5xFAD, Amyloid-β plaques, Neuroinflammation, Microglia

Background
Key pathological features of Alzheimer’s disease (AD)
are aggregates of amyloid-β peptides (Aβ) and neurofibrillary tangles (NFTs), and neurodegeneration, together
with blood-brain barrier (BBB) dysfunction, neuroinflammation, and lipid disbalance. To date, the molecular
mechanism underlying neurodegeneration in AD remains unclear. Elucidation of the dysregulated biological
mechanisms that lead to the onset and progression of
AD is critical to identify new treatment strategies [1–5].
Sphingolipids (SLs) are waxy lipids formed by a
sphingosine backbone, important for the cell membrane
architecture and for the function of transmembrane proteins. Furthermore, SLs such as ceramides (Cer) and
sphingosine-1-phosphate (S1P) are potent second messengers that regulate various important cellular processes, including cell growth and apoptosis [6–9]. Cer
are formed by two metabolic pathways: de novo synthesis initiated with the precursor palmitoyl-CoA, or catabolism of complex SLs such as sphingomyelin (SM) [10–
12]. In the cell membrane, SLs are typically organized in
microdomains, called lipid rafts, characterized by specific
SL species composition.
Several studies have analyzed lipid composition in AD
brain tissue, reporting an increase of Cer species [13–
16]. Lipid rafts enriched in Cer, isolated postmortem
from frontal cortex tissue of AD patients, showed a reduction of SM levels compared to those isolated from
the control brains [17]. Moreover, in AD brain tissue,
SM levels were reduced in brain regions particularly vulnerable to Aβ plaque formation [18–20]. Strong evidence links Aβ pathology to SL homeostasis. The
enzymes β-secretase and γ-secretase, which cleave the
amyloid precursor protein (APP) to generate Aβ, are stabilized and have an increased half-life in Cer enriched
membranes, thus increasing Aβ biogenesis [21, 22]. In
turn, Aβ can stimulate Cer production by directly activating the phosphodiesterase enzyme sphingomyelinase
which converts SM to Cer [18, 19].
Ceramide transfer proteins (CERTs) contain a steroidogenic acute regulatory protein (StAR)-related lipid
transfer (START) domain that confers the ability to
transport Cer intracellularly between the endoplasmic
reticulum (ER) and the Golgi [23]. CERTs are found in
at least two isoforms, which differ for the presence of a

26-amino acid serine-rich domain [24]. CERTs are
expressed in the central nervous system, and they are
crucial in embryogenesis and brain development [24–
26]. When CERTs’ activity is blocked pharmacologically
or genetically, by compromising the START domain of
the protein, SM production decreases significantly [27,
28]. CERTL can be secreted extracellularly and was
found to partially co-localize with serum amyloid P component (SAP) and with amyloid plaques in AD brain [29,
30]. Besides, CERTs are also potent activators of the
classical complement pathway that plays an active role
in AD pathogenesis [31]. To date, the significance of
these observations for the pathophysiology of AD remains uncertain.
In the current study, we investigated the interaction of
CERTL with APP and Aβ in vitro. Next, we explored the
effect of CERTL overexpression on SL composition,
amyloid formation, and inflammation in vivo using
adeno-associated virus (AAV)-mediated gene delivery in
the 5xFAD mouse model [32]. Our findings showed that
an increase of CERTL modulated SL levels by reducing
specific Cer and elevating SM. Notably, CERTL also affected amyloid plaque formation and brain inflammation, supporting the idea that enzymes and transporters
of the SL pathways are at the core of the pathophysiological changes observed in AD.

Material and methods
CERTL interaction with APP/Aβ
Immunoprecipitation (IP)

Wild-type HEK293 and transgenic HEK293 cells that
stably overexpress human APP695 isoform (NP_
958817.1) [33] were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with fetal bovine
serum (FBS), penicillin/streptomycin (Pen/Strep), and Lglutamine. Stable transfected HEK-APP were maintained
in G418 selective medium. Prior to the experiment, cells
were seeded in 25-cm2 flasks and maintained in serumfree DMEM for 24 h. For the homogenization, cells were
washed two times with phosphate-buffered saline (PBS),
collected in lysis buffer (25 mM Tris HCl pH 7.5150 mM
NaCl, 0.5% Triton X-100 and protease inhibitors), and
centrifuged at 20,000g for 30 min, and the resultant supernatants collect for the Bradford protein analysis. Protein extracts (100 μg) from HEK or HEK-APP were used
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for immunoprecipitation experiments. Pull down of endogenous CERTL and APP was performed with 1 μg
mAb anti CERTL (3A1-C1) [29] and anti-Aβ mAb 6E10
(Covance), respectively by 1-h incubation at room
temperature. mAb anti-syntaxin 6335 (clone 3D10,
Abcam) was used as an isotype control. Next, antimouse secondary antibodies (Eurogentec) were used to
pull down the immune complex. Thereafter, samples
were centrifuged at 20,000g for 30 min. Pellets were
washed three times in 50 μL PBS and boiled in reducing
sample buffer containing mercaptoethanol to solubilize
immunocomplexes. Then, the proteins were separated
on a Tris-HCl 4–15% gradient gel (Bio-Rad) and blotted
on nitrocellulose membrane (Millipore). Next, the membranes were probed with anti-Aβ/APP (6E10) or rabbit
pAb anti-CERTs (epitope 1–50 of human CERTs, Bethyl
Laboratories) antibodies. After 3 washes, membranes
were incubated with donkey anti-mouse IRdye 680 and
goat anti-rabbit IRdye 800 (Rockland Immunochemicals)
and scanned using the Odyssey infrared imaging system
(LI-COR Biosciences).
Neuronal culture and immunofluorescent staining

Primary neurons were cultured from 5xFAD neonates
P0 as described, with modifications [34]. After the
cortical area was dissected, the tissue was digested in
0.25% trypsin in Hank’s Balanced Salt Solution (HBSS,
Corning) for 15 min. Trypsin activity was stopped
with plating medium, DMEM (Gibco, Invitrogen) containing 10% FBS and N2 supplement. Then, the
digested tissue was passed through a cell strainer,
spun down, and cells resuspended in plating medium.
Cells were seeded onto poly-D-lysine-coated coverslips and cultured at 37 °C in a 5% CO2 atmosphere.
After 4 h, the plating medium was replaced with Neurobasal medium supplemented with B27 supplement,
Pen/Strep, and 0.5 mM L-glutamine and kept on for
10–14 days. Every other day, supplemented Neurobasal medium was partially replaced.
Neurons were fixed with 4% PFA in PBS (Thermo Scientific) at 4 °C for 10 min, permeabilized with 0.25%
Triton-X in PBS for 5 min, washed three times with PBS,
and incubated with 3% BSA for 30 min. Cells were
stained with rabbit polyclonal anti-CERTs (epitope 300–
350 of human CERTs, Bethyl Laboratories), goat antiMAP-2 (D-19) (Santa Cruz Biotechnology), and 6E10
anti APP/ Aβ [29]. The following secondary antibodies
conjugated to fluorophores were used for detection:
anti-mouse IgG Alexa 647, anti-rabbit IgG cy3, and antigoat IgG Alexa 488. Fluorescence microscopy was performed using Eclipse Ti2-E inverted microscope system
(Nikon). Images were processed using Nikon NISElements software equipped with a 3D deconvolution
program.
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Microscale thermophoresis binding analysis

Microscale thermophoresis (MST) analysis was performed in the Monolith NT.155 instrument (Nanotemper). In brief, 20 nM of NT647 labeled CERT was
incubated for 20 min at room temperature in the dark
with different concentrations of either Aβ1–42 (rPeptide
Athens) (3–100,000 nM) or control 17 kDa Lama antibody fragment (H6) (1–35,000 nM) in PBS Tween20
(0.01%). Afterward, 3–5 μL of the samples were loaded
into glass capillaries (Monolith NT Capillaries,
Cat#K002), and the thermophoresis analysis was performed (LED 40.51%, IR laser 80%). Statistical analysis
was performed with Origin8.5 Software.
Aβ aggregation assay and cell-based toxicity assay
Transmission electron microscopy (TEM)

Aβ1–42, purchased as the lyophilized salt (Bachem), was
dissolved in 0.01 M NaOH in ultrapure water to give an
Aβ1–42 stock solution of ca 0.20 mM, which was used
immediately to prepare each of the treatments. The
remaining peptide stock solution was frozen at − 20 °C
until required. Under these highly alkaline conditions,
the peptide is fully dissolved and exists only as monomers [35]. Treatments containing Aβ1–42 and/or CERTL
[29] were prepared in 0.20-μm filtered modified KrebsHenseleit (KH) medium (118.5 mM NaCl, 4.8 mM KCl,
1.2 mM MgSO4, 1.4 mM CaCl2, 11.0 mM glucose), buffered in 100 mM PIPES at pH 7.4, including 0.05% w/v
sodium azide to inhibit microbial growth. Samples were
incubated at 37 °C until their specified time points prior
to being prepared onto TEM grids. For replicate samples,
Aβ1–42 was thawed thoroughly immediately before use and
then vortexed briefly. The stock solution was centrifuged at
15,000 rpm for 5 min, and 2.0 μL was then taken ready for
concentration determination by absorbance at 280 nm, utilizing a NanoDrop 1000 spectrophotometer (Thermo). The
concentration of Aβ1–42 was calculated with the BeerLambert law and the extinction coefficient 1390 M−1 cm−1.
CERTL concentrations were determined in the same manner with a value of 107,925 M−1 cm−1 taken as the extinction coefficient using the 72 kDa recombinant CERTL
sequence (hCERTL, 1875 bp NP_005704.1).
All samples for TEM were prepared via a modified
TEM staining protocol [36]. Pre-coated S162 200 mesh
formvar/carbon-coated copper grids (Agar Scientific)
were inserted into 20.0 μL of the sample beaded onto
paraffin film for 60 s, then wicked, passed through ultrapure water, re-wicked, and placed into 30 μL 2% uranyl
acetate (in 70% ethanol), for 30 s. Following staining with
uranyl acetate, grids were removed, wicked, passed
through ultra-pure water, re-wicked, and placed into
30 μL 30% ethanol for 30 s. Grids were finally re-wicked
following this step, covered and allowed to dry for up to
24 h, prior to analysis via TEM.
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Samples for TEM were viewed on a JEOL 1230 transmission electron microscope operated at 100.0 kV (spot
size 1), equipped with a Megaview III digital camera
from Soft Imaging Systems (SIS). Images were obtained
on the iTEM universal TEM imaging platform software.
Aggregation assay

Aβ1–42 was purchased from Anaspec. The peptide was
solubilized in sterilized PBS, 0.1% trifluoroacetic acid
(TFA) at the concentration 2 mM and frozen in aliquots
at − 80 °C. Aliquots were diluted at the final concentration of 20 μM in a total volume of 400 μL containing 1
or 2.5 μM of affinity-purified recombinant CERTL [29].
Samples were kept under rotarod shacking for 1, 2, 4, 8,
12, and 24 h at 37 °C before adding 5 μL to 95 μL of thioflavin T (ThT) concentrated 20 μM, dispensed in 96-well
optical plate and measuring fluorescent excitation at
450 nm and emission 486 nm in Victor X3 plate reader
(Perkin-Elmer). Two Aβ antibodies against epitope 1–16
(6E10, Biolegend) and 17–24 (4G8, Biolegend) respectively were used to antagonize aggregation at a concentration of 0.1 mg/ml.
Toxicity assay

SH-SY5Y cells were seeded on a 96-well plate at a density of 3 × 104 cells per well in 1:1 DMEM:F12 with phenol red, 4 mM glutamine, 200 U/ml penicillin, 200 U/ml
streptomycin, MEM non-essential amino acids (100×;
Gibco), and 10% FBS and incubated at 37 °C for 24 h,
reaching up to 100% confluency, with 5% CO2. After 24
h, the medium was removed and replaced with 100 μl/
well medium without phenol-red, containing 2% FBS
and with 10 μM Aβ1–42 oligomers, and/or 1 μM CERTL,
or alone to control wells and incubated for 24 h. Ten microliters of MTT (4 mg/ml) was added to each well and
incubated at 37 °C for 3 h. MTT solution was decanted
and the formazan was extracted with 100 μl of 4:1
DMSO:EtOH. Plates were read at 570 nm, with a reference filter at 690 nm.
Generation of adeno-associated virus

Human collagen type IV alpha 3 binding protein cDNA
sequence (hCERTL, 1875 bp NP_005704.1) was cloned
into the plasmid AAV-6P-SEW a kind gift of Prof. S.
Kugler, Department of Neurology, University of Göttingen. The transgene expression was controlled by a human synapsin-1 promoter (hSYN, 480 bp), and an
internal ribosome entry site (IRES 566 bp) enabled the
co-expression of EGFP [37]. The plasmid expressing exclusively EGFP was used as a control (pAAV-EGFP).
The AAV-CERTL plasmid was sequenced by GATC Biotech laboratories and both AAVs plasmids were tested
in vitro. AAVs particles were produced as explained previously [38]. In brief, the transfer plasmids pAAV-EGFP
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or pAAV-CERTL were used to produce AAV2 particles.
Eight 15-cm petri dishes each containing 1.25 × 107 HEK
293 T cells in DMEM containing 10% fetal calf serum
(FCS) and 1% Pen/Strep (all GIBCO-Invitrogen Corp.,
New York, NY, USA) were prepared 1 day before transfection. The medium was refreshed 1 h prior to transfection to Iscove’s modified Eagle medium (IMEM)
containing 10% FCS, 1% Pen/Strep, and 1% Glutamine.
Transfer plasmids were co-transfected using polyethylenimine (PEI, MV25000; Polysciences Inc.) in a ratio of 1:
3 with the pAAV-EGFP or pAAV-CERTL resulting in a
total amount of 50 μg of plasmid DNA per plate. The
day after transfection, the medium was replaced with
fresh IMEM with 10% FCS, 1% PS, and 1% glutamine.
Two days later (3 days post-transfection), cells were harvested in Dulbecco-PBS (D-PBS, GIBCO) and lysed with
3 freeze-thaw cycles. Genomic DNA was digested by
adding 10 μg/ml DNAseI (Roche Diagnostics GmbH)
into the lysate and incubated for 1 h at 37 °C. The crude
lysate was cleared by centrifugation at 4000 rpm for 30
min. The virus was purified from the crude lysate using
the iodixanol gradient method, diluted in D-PBS/5% sucrose and concentrated using an Amicon 100 kDa
MWCO Ultra-15 device (Millipore). All AAV vectors
were stored at − 80 °C until use. Titers (genomic copies/
ml) were determined by quantitative PCR on viral DNA
primers directed against the EGFP portion (Forward:
GTCTATATCATGGCCGACAA; Reverse: CTTGAAGT
TCACCTTGATGC). The AAV particles produced with
pAAV-CERTL are referred to in this paper as AAVCERTL while the particles produced with pAAV-EGFP
are named AAV-control.

Animals

In this study, male mice were used. To investigate transduction efficiency over time, we employed 24 C57BL/6
wild-type (WT) animals. B6/SJL WT and 5xFAD animals
were obtained from the Jackson Laboratory and bred in
house using 5xFAD x non-carriers. This breeding strategy
may breed out the retinal degeneration allele Pde6brd1
from the original strain. The Jackson Lab has observed a
less robust amyloid phenotype in this strain. The 5xFAD
model carries 5 familial AD mutations, three of them in
the human APP transgene (Swedish, Florida, and London),
and two in the human presenilin-1 (PS1) transgene
(M146L and L286V mutations). These mutations lead to
an increase in Aβ peptide production [32]. Animals were
individually housed under a 12 h light/dark cycle in individually ventilated cages. One week before behavioral
tests, animals were adjusted to a reversed day-night cycle.
Food and water were provided ad libitum throughout the
study. All experiments were approved by the Animal Welfare Committee of Maastricht University (project number
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DEC2013-056 and DEC2015-002) and followed the laws,
rules, and guidelines of the Netherlands.
Stereotactic injection

The animals underwent bilateral stereotactic injections.
Mice were placed in a stereotactic head frame, and after
midline incision of the skin, two holes were drilled in
the skull in the appropriate location using bregma and
lambda as references. The layer V of the motor-sensory
frontal cortex was targeted; this was verified by light microscopy to observe the dye. Coordinates were determined as follows: anterior-posterior [AP] 0.06,
mediolateral [ML] ± 0.15, and dorsoventral [DV] − 0.1
[39]. The AAVs were injected at the dose of 1.12 × 108
transducing unit (t.u.) in the anesthetized mice at a rate
of 0.2 μL/min with a final volume of 1 μL for each side.
Behavioral procedures

The open field (OF) task was performed as described
elsewhere [40]. Briefly, locomotion activity was assessed
in a square divided into 4 equal arenas. At the start of a
trial, the animals were placed in the center of each
arena. The total distance traveled was measured under
low light conditions by a video camera connected to a
video tracking system (Ethovision Pro, Noldus).
The Y-maze spontaneous alternation (AYM) test was
conducted to assess spatial working memory. Mice were
placed randomly in one of the three arms of the Y-maze
and were left free to explore the arena for 6 min. The
number of arm entries and the number of triads were
recorded in order to calculate the percentage of alternations to measure working memory.
The elevated zero-maze (EZM) was used to measure
anxiety. It consists of a circular runway which is divided
equally into two opposite open and two opposite
enclosed arms. The mice were placed into one of the
open arms and allowed to explore the maze over a
period of 5 min. The total and relative duration (in %)
and distance traveled in the open and enclosed arms
were measured in the dark via an infrared video camera
connected to a video tracking system (Ethovision Pro,
Noldus). Percentage of time spent in the open arms was
corrected for latency to first closed arm entry.
The Y-maze spatial memory test (SYM) was performed using the same arena as described in AYM
above. One arm of the arena was closed by a removable
blockade placed in front of it. The mice were placed in
one of the open arms, which was randomized over the
groups, and allowed to explore the 2 open arms of the
maze for 5 min (pre-test). Afterward, the animal was
taken from the arena and put back into its home cage.
Five hours later, the mouse was placed back into its corresponding start arm of the arena, now with all three
arms accessible (post-test). The previously blocked arm
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was termed the “novel arm”. Memory was evaluated by
calculating the amount of time spent in the novel arm
corrected for the latency to move from the start arm to
another arm and the amount of time the animal spent in
the center of the maze [41].
Immunofluorescence staining

Mice were sacrificed by intracardial perfusion using Tyrode’s solution for the first minute, followed by fixation solution 4% paraformaldehyde (PFA) for 10 min under deep
sodium pentobarbital anesthesia (150 mg/kg). The brains
were removed and post-fixated overnight in 4% PFA fixation solution and subsequently moved every 24 h in a
buffer containing a gradually higher sucrose percentage:
10% and 20% sucrose in 0.1 M PBS. Afterwards, brains
were quickly frozen using CO2 and dissected into 16-μmthick sagittal sections using a cryostat (at − 25 °C; Leica).
All series of sections were subsequently stored at − 80 °C
until further processing. For the CERTs and neuron colocalization stain, we incubated the antibodies separately
to reduce the antibody-antigen interaction. Before the
antibodies incubation, the slice sections were fixed with
acetone 10 min and blocked with 0.3% H2O2 for 1 h. The
sections were incubated with a monoclonal NeuN primary
antibody (1:50, chemicon international Inc., Temecula,
CA, USA) overnight at 4 °C. Sections were washed 3 times
with Tris-buffered saline (TBS), TBS with 0.2% TritonX100, and TBS. Subsequently, streptavidin Alexa 594 (1:
500) applied for 1 h at room temperature. Then, rabbit
polyclonal anti-CERTs (epitope 300–350, Bethyl Laboratories) diluted 1:250 was used to detect CERTs. After
overnight incubation, and the corresponding secondary
antibody Alexa Fluor-647 (1:100) was applied for 1 h at
RT. The slices were mounted and stored in 4 °C before
taking pictures. Next immunofluorescence co-labeling was
performed with either rabbit IgG anti-Iba1 (Wako Pure
Chemical Corporation) or mouse IgG anti-glial fibrillary
acidic protein (GFAP) combined with human IgG anti-Aβ
[29]. Subsequently, the corresponding anti-rabbit or antimouse and anti-human secondary antibodies conjugated
to Alexa Fluor-594 or 488 (Jackson ImmunoReseach Laboratories) were added for 2 h. Washes were performed 3
times for 10 min in TBS, TBS with 0.2% TritonX-100, and
TBS, respectively in between the antibody incubation
steps. Densitometric analysis of the stainings was performed on sagittal brain sections at different lateral depth
(6–9 sections per animal) with ImageJ. Microglia ramification and sphericity were analyzed as described [42].
Sphingolipid analysis
High pressure liquid chromatography-tandem mass
spectrometry (HPLC-MS/MS)

Neuro-2a (N2a) were maintained and prepared for
HPLC-MS/MS as described in Supplementary methods.
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Powder aliquots of cortex, hippocampus, and cerebellum
tissue or Neuro-2a (N2a) cell pellet were homogenized
in PBS at the concentration of 10 μL/mg. Then, 50 μL of
the brain preparation (or 25 μL of plasma) were used to
measure Cer, sphinganine (SPA), sphingosine (SPH), and
sphingosine-1-phosphate (S1P) as previously described
[43, 44]. Briefly, brain preparation (or plasma) was
spiked with internal standards mixture prior to undergoing extraction. Data acquisition was done using select
ion monitor (SRM) after chromatographic separation
and electrospray ionization on the Thermo TSQ
Quantum Ultra mass spectrometer (West Palm Beach)
coupled with a Waters Acquity UPLC system (Milford)
for Cer, sphinganine (SPA), sphingosine (SPH), and
sphingosine-1-phosphate (S1P). SM data acquisition was
done using multiple reaction monitoring after chromatographic separation and electrospray ionization on the
Sciex Qtrap 5500 quadruple mass spectrometer (AB
Sciex Inc., Thornhill, Ontario, Canada) coupled with a
Shimadzu HPLC system (Shimadzu, Kyoto, Japan). Concentrations of each analyte were calculated against each
corresponding calibration curve and corrected for internal standard concentrations.
Protein extraction

Mice were terminally anesthetized with sodium pentobarbital, perfused, and the brain removed and dissected
into the cortex, hippocampus, and cerebellum. Each
brain region was then powdered in iron mortar partly
emerged in liquid nitrogen, and aliquoted. Frozen tissue
from dissected brains was sonicated in about 15 volumes
(w/v) of TBS with PhosSTOP and protein inhibitors
(Roche). Samples were centrifuged, and the TBS-soluble
fraction was aliquoted prior to freezing in liquid nitrogen and stored at − 80 °C in aliquots. The pellet was resuspended by sonication for 10 s in about 15 volumes of
TBS containing 1% Triton-X 100 (TBS-T) and protease
inhibitor cocktail. Samples were centrifuged, and the
TBS-T-soluble fraction and frozen in aliquots as described for the TBS fraction. The pellet was resuspended in 70% formic acid to 150 mg/ml based on
tissue weight, and mixed by rotation at room
temperature for 2 h. Samples were centrifuged, and the
formic acid-soluble fraction was neutralized (with 20
volumes of 1 M Tris base) and frozen in aliquots at −
80 °C. Total protein content in the TBS and TBS-T extractions was determined with Bio-Rad DC (Life Science
Group) protein assay following the manufacturer’s
instructions.
Aβ immunoassay and Western blot
Immunoassay

Microplates Microlon/F-shape REF 655092 (Greiner)
were coated with 1 μg/mL of human 3D6 [29] overnight
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at room temperature in coating buffer (sodium carbonate pH = 9.6 0.05 M NaCO3 in MQ water). After washing
plates (washing buffer 0.05% Tween- 20 in PBS were
blocked with 4% not fat dry milk and incubated with
brain homogenates or with Aβ to generate the standard
curve. Next plates were washed, incubated with 50 ng/
mL of biotinylated human 20C2 [29], and washed again.
Finally, plates were incubated with streptavidin-HRP
(Jackson ImmunoResearch Laboratories) diluted 1:8000
and developed using 3,3′,5,5′-Tetramethylbenzidine
(TMB). The absorption was measured at 450 nm within
30 min of stopping the reaction with 2 M H2SO4 using
the Perkin Elmer 2030 manager system.
Western blot

TBS and TBS-T samples corresponding to 40 μg of total
protein we loaded onto a precast TGX 4–16% gel (BioRad). Then, samples were transferred to PDVF membranes, blocked with Odyssey blocking buffer (LI-COR
Bioscience) and probed with 1 μg/mL mAb anti-Aβ
(6E10, Covance). After incubation with donkey antimouse IRdye680 (Rockland Immunochemicals) diluted
1:1000 in Odyssey blocking buffer, the membrane was
scanned and analyzed with the Odyssey imager. The intensities of the APP bands detected at 100 kDa were
measured with the Odyssey imager.
Reverse transcription polymerase chain reaction (RT-PCR)

Total RNA was isolated from 20 to 50 mg of cortex
using Trizol reagent (Invitrogen). One microgram of
total RNA was treated with DNAse I and transcribed
into cDNA (Superscript III, Invitrogen). PCR was performed in duplicate with SensiMix™ SYBR® Low-ROX
Kit (Bioline) using the set of primers reported in supplementary Table 1. Fold changes of expression relative to
control were determined after normalization to GAPDH
and Actin. Fold change was calculated by the comparative Ct method [45].
Statistical analysis

Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS 23.0 SPSS Inc.,
Chicago, IL, USA). All graphs were designed in GraphPad Prism (version 5, GraphPad Software, San Diego,
CA, USA). All data shown are expressed as mean ±
standard error of the mean (SEM). Behavioral tasks, SLs,
RT-PCR, and cytokines data were analyzed with twoway analysis of variances (ANOVA) with AAV treatment
and genotype as independent factors. Least significant
difference (LSD) was used for post hoc testing. Fluorescence amyloid-β aggregation assays were analyzed with
repeated measure ANOVA or ANOVA followed by
Dunnett’s multiple comparisons test. Comparison of
mean values from two groups was performed by an
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unpaired two-tailed Student’s t test or by Mann–
Whitney U test for non-parametric testing. P values
were considered as significant if p ≤ 0.05 and marked
with (*). Results were marked with (**) if p ≤ 0.01 or
(***) if p ≤ 0.001.

Results
CERTL directly affects Aβ aggregation and toxicity in vitro

It has been demonstrated that specific forms of CERTs
can be released extracellularly or found membrane
bound [30]. We have shown that CERTs can be found in
proximity to Aβ plaques in AD brain, where they partially co-localize with SAP and with amyloid fibrils [29].
Here, we tested whether the long isoform of CERT,
CERTL, interacts with Aβ and its precursor protein APP.
Cellular extracts of HEK-APP, expressing endogenous
CERTL, and stably expressing APP, were incubated with
(mouse) monoclonal antibodies (mAbs) against CERTL,
APP, or syntaxin 6 (used as a negative control) for immunoprecipitation (IP). Pull-down was performed with
anti-mouse antibodies for all 3 conditions. Western blot
analysis of the samples showed efficient direct IP of
CERTL and APP by their respective antibodies. APP was
detected as a band of ~ 100 kDa whereas CERTL was detected as a band of ~ 200 kDa (Fig. 1a, left panel). As a
result of co-immunoprecipitation, these two respective
bands were also found when either CERTL or APP were
pulled down, but not when syntaxin 6 was used instead
(Fig. 1a, right panel). The results, representative of three
independent experiments, showed an interaction between CERTL and APP/Aβ confirming our previous pull
down of APP with CERT in the brain lysate of AD animals manifesting severe Aβ pathology [29]. The two proteins showed partial colocalization in primary neurons of
5xFAD mice at the plasma membrane and in the perinuclear region (Fig. 1b). This was also observed in brain
sections of 5xFAD immunolabeled for CERTs and APP/
Aβ (Supplementary Figure 1A). As shown by microscale
thermophoresis (MST) analysis, CERTL also bound to
Aβ1–42 (Kd = 2.5 μM) (Fig. 1c) and by Western blot (Supplementary Figure 1B and C). Having shown that CERTL
directly binds to APP and Aβ, we next tested whether
binding of CERTL to Aβ1–42 could directly influence the
spontaneous fibrillization of Aβ1–42 by thioflavin T
(ThT) fluorescence spectrometry and TEM. In the absence of CERTL, ThT fluorescence of Aβ1–42 peaked
after 10–12 h indicating amyloid formation. With the
addition of CERTL (2.5 μM) Aβ1–42 maximum ThT
fluorescence reduced of about 75% around 24 h. In
contrast, at 1 μM concentration, CERTL was ineffective at preventing Aβ1–42 fibrillization (Fig. 1d). Fibrillization was also blocked by Aβ antibodies
(Supplementary Figure 1D).

Page 7 of 21

In addition to the ThT fluorescence assay, we studied Aβ aggregation in the presence of CERTL by
TEM. The TEM images showed that amyloid-like fibrils were observed in both conditions with and without CERTL in combination with Aβ. However, the
amyloid structure identified in the presence of CERTL
was not linear in shape and the fibril width varied
significantly (Fig. 1e, f) when compared to Aβ1–42
alone. The aggregates observed with CERTL plus
Aβ1–42 could be precursors to amyloid fibril formation, but not classic straight amyloid fibril formation
as previously reported [46].
Furthermore, using SHSY-5Y cells, we examined the
effect of CERTL on cell viability when Aβ1–42 was
present. The addition of oligomeric Aβ1–42 to the culture medium of SHSY-5Y cells resulted in a 38% decrease in viability after 24 h, as measured by MTT
reduction relative to control conditions (p < 0.01).
Interestingly, the simultaneous addition of CERTL significantly ameliorated the toxic effect of Aβ1–42
(Fig. 1g). Our results indicate that CERTL forms complexes with APP and Aβ. The interaction of CERTL
with Aβ affected spontaneous aggregation and toxicity
of the peptide.
As aforementioned, CERTs are important regulators of
cellular Cer and SM balance. For this reason, we investigated the effect of modulating CERTL levels on SL composition in vitro. After 48-h cell transfection with
pcDNA3.1 driving expression of CERTL, SM d18:1/16:0
was significantly increased while Cer were unchanged
(Fig. 1h). Furthermore, CERTL overexpression did not
affect cell viability (data not shown).
Ceramide species are increased in 5xFAD compared to
WT animals depending on brain region and acyl chain
length

The 5xFAD model carries 5 familial AD mutations.
These mutations lead to a rapid increase of Aβ peptide
production. By 6 weeks of age, mice display elevated
levels of Aβ, amyloid deposits, and age-dependent
amyloid pathology accompanied by increase of inflammatory marker levels in the CNS [47–50]. However, it
is unknown if this model shows also an increase of
Cer level in the brain as it has been reported in the
brains of AD patients [13–16]. Sphingolipid species
were determined with HPLC-MS/MS in the cortex,
hippocampus, and cerebellum of 5xFAD and wild-type
(WT) male mice at 25–26 weeks of age (Supplementary Table 1 reports complete analysis). The analysis
showed a significant elevation of Cer d18:1/16:0 levels
in the cortex and of sphinganine (SPA), S1P, Cer d18:
1/16:0, Cer d18:1/18:1, Cer 18:d1/20:0, and Cer d18:1/
22:0 in the hippocampus of the 5xFAD animals compared to WT mice (Fig. 2a, b). In the cerebellum, only
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Fig. 1 CERTL binds directly to APP and Aβ and reduces Aβ aggregation and toxicity in vitro. a Protein interaction detected using co-IP of APP
and CERTL in HEK-APP. The total cell lysate of HEK-APP cells (L) lane 1 and the total cell lysate of HEK-APP cells IP using APP/Aβ (lane 2), CERTL
(lane 3), and syntaxin (isotype control) (lane 4) antibodies were analyzed by Western blot. APP (1) and CERTs proteins were detected. The isotype
control syntaxin protein was negative. Molecular weight markers are indicated (kDa). b Immunofluorescent staining showing co-localization of
CERTs and APP/Aβ in primary neurons isolated from 5xFAD brains. Neuronal marker MAP 2 was used to immuno-label neuronal cells. DAPI was
used for nuclei staining. Scale bar 5 μm. c CERTL and Aβ1–42 interaction was measured by microscale thermophoresis. The dissociation constant
(Kd) calculated was 2.5 ± 0.3 μM. d Percentage of Thioflavin T (ThT) fluorescence intensity to detect Aβ1–42 20 μM aggregation in the absence or
presence of recombinant CERTL 1 or 2.5 μM at different time points. Each data point represents the percentage of mean fluorescent intensity of
three wells (repeated measures ANOVA; Dunnett’s multiple comparisons test **p < 0.01, ***p < 0.001). e, f TEM analysis of 2 μM Aβ1–42
aggregation in the absence and presence of 0.1 μM CERTL showed a different aggregation pattern quantified by Aβ width (Student’s t test ***p <
0.001). g Measurement of cell metabolic activity of SH-SY5Y by MTT assay in cells incubated with medium alone (control) or medium containing
10 μM Aβ1–42, Aβ1–42, and 1 μM CERTL, or CERTL alone for 24 h. Graph bar expressed as means ± S.E.M % of control N = 5–10 (one-way ANOVA,
Bonferroni correction *p < 0.05; **p < 0.01). h SM d18:1/16:0, SM d18:1/18:1, SM d18:1/18:0, SM d18:1/24:1, and SM d18:1/24:0 measured by HPLCMS/MS in N2a cells after 48-h transfection with vector control or pcDNA-CERTL. Graph bar expressed as means ± S.E.M % of control N = 4/group
(one-way ANOVA, Holm-Sidak’s multiple comparisons test ***p < 0.001)

S1P levels were found to be significantly higher in the
5xFAD animals compared to controls. These results
indicate that at that specific age and disease stage of

the animals, the cortex and the hippocampus are
more susceptible to increase of Cer levels while the
cerebellum is less affected. This suggests that the
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increase of Cer levels correlate with amyloid burden.
In line, the cortex and hippocampus are the areas
where the plaques are first reported to appear in this
model [32]. Quantification of CERT levels in the cortex by immunoassay showed a significant reduction of
the protein concentration in AD brains compared to
controls at 25–26 weeks of age [51]. CERTs reduction
was not observed in cerebellum (Fig. 2d). Our data
suggest that SL metabolism is shifted towards increased production of Cer at different degrees depending on the brain region. Furthermore, CERT
concentration was reduced in the cortex of 5xFAD
mice compared to WT.
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AAV-mediated neuronal expression of CERTL in mouse
brain

To test the hypothesis that increasing CERTL levels in
the cortex counteract the SL dysbalance in 5xFAD animals and Aβ formation, we generated AAV2 particles
carrying the CERTL cDNA sequence controlled by the
neuron-specific synapsin promoter (Fig. 3a). The AAVCERTL was tested in vitro on cortical rat primary cell
culture, proving to effectively transduce neurons (Supplementary Figure 2A). Next, 8-week-old WT animals
underwent stereotactic surgery and AAV-CERTL or
AAV-control were injected in the layer V of the motor
cortex (Supplementary Figure 2B). The transduction

Fig. 2 Ceramide levels are increased in 5xFAD compared to WT animals depending on brain region and acyl chain length while CERT levels are
reduced. Sphingolipids levels were measured in the hippocampus (a), cortex (b), and cerebellum (c) by HPLC-MS/MS of WT and 5xFAD mice.
Sphingolipids were classified based on acyl chain number of carbons (Sph, S1P, SPA, Cer d18:1/16:0, Cer d18:1/18:1, Cer d18:1/20:0, Cer d18:1/22:0,
and Cer d18:1/24:0). CERT was quantified by ELISA in protein extract of cortex and cerebellum of WT and 5xFAD animals. Bars represent the
mean ± S.E.M per group N = 11–12 (Student’s t test *p < 0.05; **p < 0.01)
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efficiency was evaluated 1, 2, 6, and 12 weeks postinjection by immunohistochemistry (Supplementary Figure 1C-D) and by RT-PCR (Supplementary Figure 1E).
The AAV-CERTL was shown to effectively transduce
neurons and expressed the CERTL protein for at least
12 weeks. The AAVs were then injected in 5xFAD mice
in a similar fashion. Mice underwent stereotactic surgery
for CNS administration of AAV particles at 12–13 weeks
of age and were monitored for 12 weeks. Layer V of the
frontal cortex was targeted since the Aβ accumulation is
the most severe there [32] and CERT levels are reduced
in this mouse model. After 12 weeks CERT overexpression was confirmed by immunofluorescence (Fig. 3b)
and by Western blot analysis (Fig. 3c, d). The immunolabeling of CERTs, with neuronal marker NeuN, showed
colocalization in the layer V of the motor cortex. Relative quantification of CERTs levels in cortex homogenates by Western blot illustrated a significant increase of
CERTs levels in AAV-CERTL-treated groups (Fig. 3d).
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5XFAD and WT mice injected with AAV-CERTL and AAVWT did not show behavioral abnormalities

At week 10 post-injection, mice were challenged with a
behavioral test battery in the following sequence: open
field (OF) for assessing locomotion activity, Y-maze
spontaneous alternation (AYM), and SYM for assessing
spatial memory and elevated zero-maze (EZM) for
examining anxiety (Fig. 4a–e). It has been reported that
5xFAD mice exhibit changes in hippocampus-dependent
spatial working memory by 16 to 24 weeks of age [32].
However, in our hands, no difference was found in the
performance of 5xFAD compared to WT in locomotion
(Fig. 4b), memory (Fig. 4c, e), and anxiety (Fig. 4d). Our
data showed that the WT animals treated with the control virus performed above the 50% chance level in the
AYM (Fig. 4c). Furthermore, in the OF, the AAVCERTL attenuated 5xFAD hyperactivity, even though
5xFAD treated with AAV-control did not perform significantly different from WT animals (Fig. 4b, two-way

Fig. 3 AAV-mediated neuronal expression of CERTL in mouse brain. a The recombinant genomes of the two AAV-2 vectors. ➔ Abbreviations:
From left to right, ITR, inverted terminal repeats; hSYN1, human synapsin 1 gene promoter; CERTL, cDNA sequence coding for ceramide transfer
protein long isoform (hCERTL, 1875 bp NP_005704.1); IRES, internal ribosome sequence for translation initiation; EGFP, cDNA coding for enhanced
green fluorescent protein (GFP); WPRE, woodchuck hepatitis virus posttranscriptional control element; bGH, bovine growth hormone genederived polyadenylation site; TB, synthetic transcription blocker. b Representative images of immunofluorescent staining of cortical brain area
from 5xFAD animals treated with AAV-control or AAV-CERTL. Section was co-stain for CERTs protein (green), neuronal marker NeuN (red). Scale
bar 200 μM and 50 μM. c Western blot showing band intensities of CERTs and GAPDH. d Relative quantification of CERTs levels normalized to
GAPDH in cortical protein extract from WT and 5xFAD animals treated with AAV-control or AAV-CERTL. Bars represent mean one representative
experiment with 5–7 samples per group (Mann–Whitney test, *p < 0.05)
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ANOVA, interaction F = 4.170, p = 0.0463). Overall,
these data suggest that no detrimental behavioral effects
in the animals were observed after CERTL overexpression.
AAV-CERTL decreased Cer d18:1/16:0 and increased SM
levels in the cortex

One of the main functions of CERTs is to shuttle Cer
from the ER to the Golgi [23]. It has been reported that
toxic increase of Cer species in the muscle can be attenuated by overexpressing hCERT cDNA [52]. HPLC-MS/
MS analysis of brain cortex tissue revealed a significant
reduction of Cer d18:1/16:0 level due to CERTL overexpression (p < 0.05). This effect was not observed in WT
animals but only in 5xFAD animals where Cer d18:1/16:
0 level was significantly elevated (p < 0.01). This transport of Cer to the Golgi is crucial for the de novo synthesis of more complex SLs such as SM. Previous data
from in vitro experiments reported that blocking CERTs
function SM levels would significantly decrease [27].
Hence, if CERTs activity is enhanced, we expected an increase in SM levels. As reported above, we found that
in vitro overexpression of CERTL increased the levels of
certain species of SM. SL analysis of the cortex showed
that the levels of most of SM species (SM d18:1/16:0 p <
0.001, SM d18:1/18:0 p < 0.001, SM d18:1/18:1 p < 0.01,
SM d18:1/20:0 p < 0.05, SM d18:1/22:0 p < 0.05, and SM
d18:1/24:1 p < 0.01) were increased in AAV-CERTL
treated animals (Fig. 5). The only SM species not found
significantly elevated was the SM d18:1/24:0, whose precursor Cer d18:1/24:0 has been reported to be poorly
transferred by CERTs [53].
These data suggest that CERTL overexpression is effective in reducing Cer increase by intensifying the transfer to
the Golgi, which leads to an increase of SM. While the
Cer attenuation was restricted to a pathological increase
of Cer d18:1/16:0 level, SM elevation was consistent in all
AAV-CERTL-treated animals. This shift in SL composition did not affect apoptosis markers in the cortex quantified by RT-PCR (Supplementary Figure 6A).
AAV-CERTL reduces Aβ levels by decreasing APP cleavage
in the cortex of 5xFAD mice

Since our previous data indicated that CERTL could be
released to the extracellular milieu and directly affects
Aβ aggregation and toxicity in vitro, we investigated the
effect of CERTL overexpression on Aβ deposition.
(Fig. 6a). Statistical analysis showed no significant difference in plaque load between the 5xFAD groups at 24–
26 weeks of age (Fig. 6b). However, the percentage of
small plaques size (10–25 μm) was reduced (p < 0.05) in
AAV-CERTL-treated 5xFAD brains (Fig. 6c). Furthermore, Aβ quantification of brain homogenate in TBS
soluble and TBS-T soluble fraction showed that Aβ
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levels were reduced in samples treated with AAVCERTL (p = 0.04 and p = 0.03, respectively), while in the
formic acid soluble fraction no change was observed
(p = 0.29) (Fig. 6d). Since it has been reported that APP
cleavage can be affected by Cer composition [21, 22], we
investigated if the reduction of Cer and increase of SM
levels mediated by AAV-CERTL is associated with altered processing of APP. The ratio Aβ/FL-APP was decreased in CERTL overexpressing mice implying a
reduction of Aβ biogenesis or increased clearance of Aβ
(p < 0.01). Since the CTFβ is the product of β-secretase
cleavage of APP and the immediate precursor of Aβ formation [54], the ratio of CTFβ/FL-APP bands’ intensities
was used to assess APP processing by β- and γ-secretase.
The CTFβ/FL-APP was found an increase in AAVCERTL treated 5xFAD animals (p < 0.05) (Fig. 6e).
Meanwhile, the ratio Aβ/CTFβ was reduced in brains of
CERTL overexpressing mice (p < 0.01) (Fig. 6e and Supplementary Figure 5). These results indicate that AAVCERTL affects the proteolytic processing of APP by βand/or γ-secretase.
These results show that a specific balance of Cer to
SM and/or interaction of CERTL with APP is critical for
APP cleavage and Aβ biogenesis.
Four weeks of administration of CERTs inhibitor
(HPA-12) exacerbates Cer and Aβ pathology in AD
transgenic mice

To test if efficient Cer trafficking from the ER to
the Golgi is vital in the regulation of the Cer levels
and Aβ formation, we administered the CERTs
inhibitor N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl)
dodecanamide (HPA-12) for 4 weeks to AD transgenic
mice. As expected Cer d18:1/16:0, Cer d18:1/20:0, Cer
d18:1/22:0, and Cer d18:1/24:1 levels were found an increase in the brain (Fig. 7a). Moreover, Aβ levels were increased by 117% in the TBS soluble fraction (p < 0.05) and
by 47% in the TBS-T soluble fraction of brain homogenates (*p < 0.05) of CERTs inhibitor-treated AD animals.
No significant changes were found in the FA insoluble
fraction (Fig. 7b).
These data suggest that efficient Cer transfer from
ER to trans-Golgi is critical to control Cer levels
and thereafter APP processing. Pharmacogical interference with CERT activity augments Cer levels and
increases substantially Aβ biogenesis and/or
fibrillization.
AAV-CERTL reduces microglia immunoreactivity as shown
by Iba1 labeling and CD86 expression

We have observed that CERTs are associated with Aβ
plaques in AD brain where microglia cells are engaged [29]. Thus, we investigated if microglia cells
were affected by CERTL overexpression in the cortex.
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Fig. 4 No behavioral abnormalities 10 weeks after injection of AAV-CERTL. a The effects of CERTL over-expression were investigated in 30 5xFAD
and 30 WT males. Mice were bilaterally injected at 12–13 weeks of age with AAV-CERTL or AAV-control particles at the dose 1.12 × 10E8
transducing unit (t.u.). Starting at week 22 of age, animals were challenged with the following behavioral tests: open field (OF) for locomotion
activity, alternate Y-maze (AYM) and spatial Y-maze (SYM) for spatial memory, and elevated zero-maze (EZM) for anxiety. b Locomotion expressed
as distance traveled in OF task. c The graph shows the results of the working memory in the AYM task as a percentage of correct alternation in
the first four triads. Percentage were compared to 50% chance levels (one sample t test **p < 0.01). d Anxiety was assessed, measuring the
percentage of time spent in the closed arm in EZM. e Memory was measured in SYM expressed as a percentage of time spent in the novel arm.
Bars represent the means ± S.E.M per group N = 10–20 (two-way ANOVA, interaction effect F = 4.170 p = 0.0463, LSD, *p < 0.05)

To achieve this aim, brain sections were analyzed for
Iba1 reactivity. AAV-CERTL-treated brains had a decreased immunoreactivity to Iba1 (percentage of area
p < 0.001) (Fig. 8a–c). Iba1 is considered a constitutive
marker for microglia, which is highly increased in
5xFAD animals compared to WT. [55, 56] Furthermore, it has been shown to be important for membrane ruffling, a process crucial for macrophage and
microglia motility and chemotaxis [57]. We further
characterized microglia based on ramifications and
sphericity. The analysis showed that microglia of

AAV-CERTL-injected mice had longer ramifications
and lower sphericity index (Fig. 8d, e). To investigate
if AAV-CERTL affected other microglia membrane
markers, we analyzed cortex tissue by RT-PCR. We
quantified the CD86 membrane marker, which is an
indicator for microglia pro-inflammatory polarization.
Statistical analysis showed that CD86 was increased in
AAV-control-treated 5xFAD animals compared to
AAV-control-treated WTs and that AAV-CERTL specifically decreased CD86 in the 5xFAD group
(Fig. 8f).
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Fig. 5 AAV-CERTL reduces Cer d18:1/16:0 and increases sphingomyelin species in the cortex. Sphingolipids levels were measured in the cortex by
HPLC-MS/MS. Ceramides were classified based on acyl chain number of carbons (Cer d18:1/16:0, Cer d18:1/18:0, Cer d18:1/18:1, Cer d18:1/20:0,
Cer d18:1/22:0, and Cer d18:1/24:1) as well as sphingomyelin (SM d18:1/16:0, SM d18:1/18:0, SM d18:1/18:1, SM d18:1/20:0, SM d18:1/22:0, and SM
d18:1/24:1). Ceramide levels were expressed as ng/mg tissue, while sphingomyelins were expressed as pmol/mg tissue. Bars represent the
mean ± S.E.M per group N = 5–12 (two-way ANOVA, LSD, significant effects, *p < 0.05; **p < 0.01; ***p < 0.001)

Next, we analyzed cytokines levels in brain homogenate using multiplex technology. The assay did not reveal
any significant effect of AAV-CERTL treatment. However, we observed a significant increment of IL-1β (p <
0.01) and a significant reduction of IL-4 (p < 0.05) when
comparing WT to 5xFAD animals in AAV-control
treated groups (Supplementary Figure 6A).
These results indicate overall that AAV-CERTL decreases pro-inflammatory processes in microglia.
AAV-CERTL does not change the immunoreactivity of
astrocytes as shown by GFAP labeling in the cortex of
5xFAD mice

Reactive astrocytes have been described as a pathological hallmark that generally occurs in response to
neurodegeneration in AD [58]. To determine the extent of astrocytosis in the 5xFAD mouse brain
treated with AAV-CERTL compared to control, we
performed immunofluorescence GFAP labeling on
sagittal brain sections (Fig. 8g). Densitometric and

particle analysis performed with ImageJ showed a
47% reduction in astrocyte immunoreactivity, which
was not statistically significant (Fig. 6h). However, as
previously reported, we observed a 3-fold increase of
GFAP immunoreactivity in the 5xFAD animals compared to WT controls [32, 59].

Discussion
In this work, we provide evidence suggesting that
CERTL plays an important role in characteristic processes of AD by affecting Aβ production and aggregation, neuroinflammation, and SL disbalance typical of
AD. Our data show that the pathological increase of
Cer d18:1/16:0 can be reduced to normal levels by
upregulating CERTL. The reduction of Cer levels also
proved to be effective in attenuating Aβ formation.
Furthermore, CERTL overexpression in neurons revealed that CERTL can downregulate membrane
markers indicating a pro-inflammatory status in
microglia.
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Fig. 6 Neuronal increase of CERTL reduces Aβ by decreasing APP cleavage. a Representative photomicrographs of sagittal brain sections imaging
the motor sensory cortex (M1 and M2) stained for nuclei in blue and Aβ plaques in green. All photomicrographs were exposed and processed
identically. Scale bar represents 200 and 50 μm (from right to left). b Immunofluorescent quantification of plaques measured by the percentage
of area, plaques counts/mm2. c Frequency distribution of plaques based on size (10–25 μm) (error bars represent ± SEM of 4–6 animals per
experimental condition, ANOVA, Bonferroni correction, significant effects, *p < 0.05; **p < 0.01). d Aβ quantification in three extraction buffers, BS,
TBS-T, and formic acid (FA) by ELISA showed that Aβ was significantly reduced in the soluble fractions in the cortex but not in the insoluble
fraction (Student’s t test *p < 0.05). e Western blot analysis of TBS cortex homogenate stained with 6E10 antibody showed that ratios of amyloid
Aβ/FL-APP and Aβ/CTFβ are reduced while CTFβ/FL-APP is increased in AAV-CERTL-treated animals while CTFβ/FL-APP is increased. Error bars
represent ± SEM of 5 animals per experimental condition (Student’s t test *p < 0.05; **p < 0.01) (full length amyloid precursor protein = FL-APP;
amyloid-β peptide = Aβ; C-terminal fragment β = CFTβ). Western blot membranes are shown in Supplementary Figure 5
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Fig. 7 CERTs inhibitor increases Cer and Aβ levels in the brain of transgenic AD mice. a Sphingolipid levels were measured in the
cortex by HPLC-MS/MS. Ceramides were classified based on acyl chain number of carbons (Cer d18:1/16:0, Cer d18:1/18:0, Cer d18:1/
22:0, and Cer d18:1/24:1) and levels were expressed as pmol/mg tissue. Bars represent the mean ± S.E.M per group N = 10–12
(Student’s t test *p < 0.05) Aβ quantification in hippocampus homogenate extracted in three buffers, TBS, TBS-T, and formic acid (FA)
by enzyme-linked immunoassays. Means of each fraction were compared with unpaired t test (control N = 10; HPA-12
N = 13; *p < 0.05)

It has previously been reported that APP can interact
with extracellular matrix proteins like collagen I [60, 61].
This interaction is thought to be important in neuronal
cell to cell adhesion with APP functioning as an anchor
[62]. CERTL is known to be crucial in stabilizing the
basal membrane [63]. We previously reported that
CERTs can be found in close location to plaques in AD
brains, where they co-localize with amyloid fibrils [29].
In line with this, we found that APP can interact with
CERTL and form complexes that can be immuneprecipitated. Also Aβ can bind to a variety of biomolecules, including lipids, proteins, and proteoglycans [64].
Here, we show that CERTL binds directly to Aβ peptides
and that this interaction affects Aβ fibrillization by organizing Aβ into less neurotoxic aggregates.
Manipulation of CNS SL metabolism can be challenging. Removal or addition of genes encoding for enzymes and transporters in the SL pathway can be

deleterious for brain function [65, 66]. A previous report
where human acid sphingomyelinase was increased in
the brain of rodents and primates showed that motor
function could be severely affected [67]. In contrast, in
our study, behavioral testing at 9–10 weeks post AAV
particle injection revealed no detectable side effects
when comparing AAV-CERTL- to AAV-control-treated
animals in various memory- and anxiety-related behavioral tasks. Of note though, we found a significant reduction of locomotor activity in the 5xFAD due to AAVCERTL treatment. It has been reported that 5xFAD animals exhibit a hyperactive behavior compared to control
animals even though this specific behavior is not well
understood and translation to human symptoms is unclear [68]. However, the question whether AAV-CERTL
could improve memory or other behavioral deficits observed in the 5xFAD model could not be answered by
our data. No significant impairments in spatial memory
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(See figure on previous page.)Fig. 8 AAV-CERTL reduces microglia reactivity to Iba1 and CD86 expression levels but has no significant effect on
GFAP immunoreactivity in the cortex of 5xFAD mice. a Representative photomicrograph of Iba1 staining in the cortical motor sensory region of
5xFAD animals treated with AAV-control or AAV-CERTL (scale bar 50 μm). b Densitometric analysis of Iba1 staining represented as a percentage of
the area (AAV-control n = 6 and AAV-CERTL n = 4 for WT and 5xFAD groups). c Densitometric analysis of Iba1 staining represented as number of
positive Iba1 cells/mm2 (AAV-control n = 6 and AAV-CERTL n = 4 for 5xFAD groups). d Length of microglia ramification and sphericity per cell in
AAV-control or AAV-CERTL. Morphological analysis was performed on 3–5 pictures/group. e Illustrations of the microglia morphological analysis
applied to a fluorescent photomicrograph captured with × 60 objective with a single cell cropped to show details. Scale bar = 20. f Analysis of
gene expression of membrane markers CD86 (4–5 number of animals per group). g Representative photomicrographs of GFAP staining in the
cortical motor sensory region of 5xFAD animals treated with AAV-control or AAV-CERTL (scale bar 50 μm). h Densitometric analysis of GFAP
staining represented as a percentage of the area (AAV-control n = 6 and AAV-CERTL n = 4 for WT and 5xFAD groups). Bars represent the mean ±
S.E.M per group (two-way ANOVA, LSD, significant effects, *p < 0.05; **p < 0.01)

were detected in the AYM and the SYM tests. In the original 5xFAD line (on a hybrid B6SJL background and
carrying the Pde6b gene), Jawhar et al. reported deficits
of working memory, assessed by a cross-maze test, to
appear at 6 months [69]. In contrast, the behavioral
phenotype of the 5xFAD line on a C57BL/6J background
and without the Pde6b gene, are much less clear. Richard et al. reported in this last line of 5xFAD spatial
memory deficits were only visible after 7 months of age
[70]. Others reported spatial memory impairment at an
earlier age when using the water maze but with a very
small difference between WT and 5xFAD [71, 72]. In
the present study, none of the groups tested in the SYM
test performed above chance level indicating lack of recognition in all groups examined. However, in the AYM,
the WT group treated with AAV-control performed
above chance level (mean of 68%), which in the AYM is
considered to be 50%. As such, future studies should
additionally assess shorter inter-trial intervals in this
respect.
Cer generation is abnormal in AD, causing an increase
in Cer formation [15, 73]. Furthermore, an accumulating
body of evidence consistently reported a global rise in
Cer levels in specific brain regions of AD patients [13,
74, 75]. In agreement with these observations, we found
that 5xFAD transgenic mice at 6 months of age also
showed an increase of Cer d18:1/16:0 in the cortex and
of several Cer species in the hippocampus (Cer d18:1/16:
0, Cer d18:1/18:1, Cer d18:1/20:0 and Cer d18:1/22:0).
Previously, other studies showed increased brain Cer
levels in different transgenic AD models (APP, PS1, and
PS1-APP mutated mice) [76]. This suggests that there is
a causal relationship between amyloid pathology and
Cer imbalance.
In this study, we report that increasing Cer trafficking
from the ER to the Golgi by overexpressing CERTL reversed the pathological increase of Cer in the cortex. A
similar effect of CERTs overexpression in Cer elevation
state has been reported in a lipotoxic mouse model
where muscle cells in overload Cer status were rescued
by increasing the expression of hCERT [52]. In AD
brains, we observed that CERTL reduced 11% of the total
Cer content restoring it close to normal levels. In

particular, Cer d18:1/16:0 was the most affected species
by AAV-CERTL being reduced up to 35%. These results
demonstrate the importance of physiological ER-toGolgi Cer traffic in preserving the physiological balance
of Cer levels in AD pathology.
The soluble Aβ forms were reduced in the CERTLtreated animals, whereas the insoluble Aβ forms were
not altered by the treatment. This reduction in the soluble forms could be explained in two ways: (i) the 11%
reduction of total Cer due to CERTL overexpression and
(ii) CERTL interaction with Aβ. As aforementioned, the
amyloidogenic cleavage of APP is favored resulting in
more Aβ formation in Cer enriched conditions [21, 22].
In our study, the total Cer reduction may have affected
the secretases activity in the opposite way. We found
that the Aβ/APP ratio, which describes the APP processing to form Aβ, was lower in AAV-CERTL animals implying that lesser APP is processed to generate the Aβ
peptide. Importantly, APP processing takes place in different cell compartments not only on the cell surface
[77] and the Cer shift is not confined to the ER compartment but can affect the whole cell [78, 79]. This conclusion was further confirmed by pharmacological
inhibition of CERT Cer transfer activity with CERT inhibitor HPA-12. Recently, the pharmacokinetics of
HPA-12 was described, and it was proven that the compound reaches the brain intact [25]. Here, we found that
after 4 weeks, the treatment of HPA-12 increases Cer
and Aβ levels.
It is now thought that one of the crucial processes in
the development and exacerbation of AD is neuroinflammation [80]. Our lab demonstrated that CERTL interacts with SAP which belongs to the pentraxin family
of the innate immune system [29]. Additionally, we reported that CERTL can activate the complement system
[31]. Here, we found that AAV-CERTL influenced
microglia activation even though CERTL was specifically expressed in neurons under the control of the
synapsin promoter. It has been consistently reported
that 5xFAD microglia are polarized towards a more
pro-inflammatory status, in response to the extensive
plaque formation. Consequently, the Iba1 microglia
marker is highly expressed in AD models [55, 56]. Our
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findings suggest that CERTL could play a role in the
cross-talk between neurons and microglia. Interestingly,
neuronal-derived CERTL activity is exerted only when
there is an inflammatory reaction ongoing by reducing
membrane markers for the pro/inflammatory status of
microglia. Nevertheless, it remains unclear by which
mechanism AAV-CERTL decreased Iba1- and CD86positive cells. Here, we propose two hypotheses. First,
the reduction of Iba1 and CD86 is a direct action of
CERTL on microglia activation status once secreted by
neurons. It is known that forms of CERTL can be released in the extracellular space [30]. The second, Iba1
and CD86 are decreased because of a modified by shifts
in Cer and SM composition or other indirect effects
like reduction of Aβ levels. In the CNS, there is an
extensive cross-talk ongoing between neurons and
microglia, which takes advantage of lipid vesicles.
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Furthermore, toxic Aβ has also been reported among
the content of exosome and reduction of exosome secretion was correlated to Aβ reduction [81, 82].
Similarly, to microglia, also astrocyte activation was reduced by AAV-CERTL, even though not significantly.
During inflammation astrocytes are enriched in Cer.
They seem to produce the pro-apoptotic Cer d18:1/16:0
[83, 84]. Further, reactive astrocytes release extracellular
vesicle enriched in Cer that carry Aβ peptides [84].
These specific extracellular vesicles isolated from brains
of 5xFAD mice showed to be particularly toxic for
neurons.
Limitations

The limitations of this study are three folded. First, we
did not detect memory difference between WT and
5xFAD. This could be due to our in-house breeding

Fig. 9 Schematic model of CERTL action in AD. a CERTL concentration is decreased in AD neuronal cells. Consequently, the transport of Cer to
the Golgi is impaired and Cer accumulates in the cell. Cer elevation stabilizes and favors the secretases activity. The amyloidogenic APP
processing is favored and Aβ is produced. The neighboring microglia changes the resting status to activate. b By overexpressing CERTL, the
physiological transfer of Cer from the ER to the Golgi is restored favoring SM synthesis, which is intensified. The reduction of Cer levels in
neuronal cells diminished secretases activity, reducing Aβ biogenesis. The interaction between CERTL and APP may be important in stabilizing
APP in the membrane and in protecting APP from secretase activity. Furthermore, CERTL affects Aβ fibrilization by organizing Aβ into less
neurotoxic aggregates that may be cleared from the brain more easily and reduces the number of activated microglia
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approach, which is explained in material and methods
section. We adopted a breeding scheme where the Pde6b
gene, which is associated to retinal degeneration, was
bred out of the genetic background of the 5xFAD transgenic mice. The Pde6b gene is thought to be crucial for
early detection of memory impairments. The second
limitation is connected to the first. Since no memory impairment was detected, it is unclear if the AAV-CERTL
would protect from memory decline. For this purpose,
animals could be tested at older age and the AAVCERTL could be injected in the hippocampus. This
follow-up study would be of interest also because the
hippocampus, as we show for the first time in this study,
is particularly affected by the Cer pathology in 5xFAD
males. The third limitation is the effect of AAV-CERTL
on astrocytes. While we had sufficient statistical power
to detect the microglia changes, astrocytes denoted a
similar trend, which was not statistically significant.
These three limitations set the ground for future studies.

Conclusion
In conclusion, by increasing CERTL expression in neuronal cells, we were able to increase SM production and
reduce Cer d18:1/16:0 especially in the CNS. Next, after
proving that CERTL binds and modifies Aβ aggregation
in vitro, we observed that administration of AAVCERTL in AD animals reduced Aβ production by at least
2 mechanisms: by altering SL composition and by direct
interaction with APP in 5xFAD animals. Moreover, we
reported a new immune role of CERTL. AAV-CERTL decreased membrane markers important for the pro/inflammatory status of microglia. Overall, our experiments
are the first to demonstrate that an increase of CERTL
modulates SL levels and affects amyloid plaque formation and brain inflammation in AD (see the model in
Fig. 9). These data open research pathways for therapeutic targets of AD and related neurodegenerative
diseases.
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